{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:50:35Z","timestamp":1787032235822,"version":"build-2736575974"},"reference-count":25,"publisher":"Becaris Publishing Limited","issue":"6","funder":[{"name":"Janssen Global Services"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    We compared the effectiveness of teclistamab versus real-world physician\u2019s choice of therapy (RWPC) in triple-class exposed\u00a0relapsed\/refractory multiple myeloma.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment\u00a0were compared.\n                    <jats:bold>Results:<\/jats:bold>\n                    After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n\u00a0=\u00a0165; RWPC, n\u00a0=\u00a0364 [766 observations]). Teclistamab\u00a0treated patients had numerically better overall survival\u00a0(hazard ratio [HR]: 0.82 [95% CI: 0.59\u20131.14]; p\u00a0=\u00a00.233) and significantly greater progression-free survival (HR: 0.43 [0.33\u20130.56]; p\u00a0&lt;\u00a00.0001) and time to next treatment (HR: 0.36 [0.27\u20130.49]; p\u00a0&lt;\u00a00.0001) versus the RWPC cohort.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed\/refractory multiple myeloma.\n                  <\/jats:p>","DOI":"10.57264\/cer-2022-0186","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T03:34:58Z","timestamp":1682652898000},"source":"Crossref","is-referenced-by-count":14,"title":["Teclistamab versus real-world physician\u2019s choice of therapy in triple-class exposed relapsed\/refractory multiple myeloma"],"prefix":"10.57264","volume":"12","author":[{"given":"Amrita","family":"Krishnan","sequence":"first","affiliation":[{"name":"Judy and Bernard Briskin Center for Multiple Myeloma Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA\u00a091010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K","family":"Nooka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA\u00a030322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai School of Medicine, New York, NY\u00a010029-5674, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred L","family":"Garfall","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Division of Hematology\/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA\u00a019104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G","family":"Martin","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center, Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, San Francisco, CA\u00a094143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Nair","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, B-2340, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwu","family":"Lin","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Horsham, PA\u00a019044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqin","family":"Qi","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Titusville, NJ\u00a008560, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Londhe","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Titusville, NJ\u00a008560, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Pei","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Raritan, NJ\u00a008869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ammann","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ\u00a008869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Raritan, NJ\u00a008869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Smit","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Horsham, PA\u00a019044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trilok","family":"Parekh","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Bridgewater, NJ\u00a008869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Marshall","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ\u00a008869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Slavcev","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ\u00a008869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z","family":"Usmani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY\u00a010065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.3390\/curroncol29070355","article-title":"Clinical management of triple-class refractory multiple myeloma: a review of current strategies and emerging therapies","volume":"29","author":"Stalker ME","year":"2022","unstructured":"Stalker ME, Mark TM. Clinical management of triple-class refractory multiple myeloma: a review of current strategies and emerging therapies. Curr. Oncol. 29, 4464\u20134477 (2022).","journal-title":"Curr. Oncol."},{"key":"e_1_3_8_4_2","volume-title":"Cancer Facts and Figures 2020.","author":"American Cancer Society","year":"2020","unstructured":"American Cancer Society. Cancer Facts and Figures 2020. American Cancer Society, GA, USA (2020). www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2020\/cancer-facts-and-figures-2020.pdf"},{"key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle RA","year":"2008","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. Blood 111, 2962\u20132972 (2008).","journal-title":"Blood"},{"key":"e_1_3_8_6_2","doi-asserted-by":"crossref","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Multiple myeloma. Version 5.2022. www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1445","DOI":"10.6004\/jnccn.2003.0003"},{"key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.clinthera.2021.09.013","article-title":"Treatment patterns and outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma: findings from the multinational ITEMISE study","volume":"43","author":"Dhanasiri S","year":"2021","unstructured":"Dhanasiri S, Hollier-Hann G, Stothard C, Dhanda DS, Davies FE, Rodriguez-Otero P. Treatment patterns and outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma: findings from the multinational ITEMISE study. Clin. Ther. 43, 1983\u20131996.e3 (2021).","journal-title":"Clin. Ther."},{"key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos MV","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 36, 1371\u20131376 (2022).","journal-title":"Leukemia"},{"key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, Phase II study","volume":"21","author":"Lonial S","year":"2020","unstructured":"Lonial S, Lee HC, Badros A Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, Phase II study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari A","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 381, 727\u2013738 (2019).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin T","year":"2022","unstructured":"Martin T, Usmani SZ, Berdeja JG Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41(6), 1265\u20131274 (2022).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_8_13_2","first-page":"1","volume-title":"Summary of Product Characteristics.","author":"Janssen Biologics B.V","unstructured":"Janssen Biologics B.V. TECVAYLI. Summary of Product Characteristics. European Medicines Agency, 1\u201349. www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf"},{"key":"e_1_3_8_14_2","volume-title":"TECVAYLI (teclistamab-cqyv).","author":"Janssen Biotech, Inc","year":"2022","unstructured":"Janssen Biotech, Inc. TECVAYLI (teclistamab-cqyv). Janssen Biotech, Inc, PA, USA (2022)."},{"key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1080\/03007995.2022.2100651","article-title":"Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"38","author":"Costa LJ","year":"2022","unstructured":"Costa LJ, Hari P, Berdeja JG Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. Curr. Med. Res. Opin. 38(10), 1759\u20131767 (2022).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jha2.312","article-title":"Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma","volume":"3","author":"Martin T","year":"2021","unstructured":"Martin T, Krishnan A, Yong K Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. EJHaem 3, 97\u2013108 (2021).","journal-title":"EJHaem"},{"key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","article-title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"37","author":"Martin T","year":"2021","unstructured":"Martin T, Usmani SZ, Schecter JM Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr. Med. Res. Opin. 37, 1779\u20131788 (2021).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0045"},{"key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.clml.2022.04.025","article-title":"Matching-adjusted indirect treatment comparison to assess the comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 versus belantamab mafodotin in DREAMM-2, selinexor-dexamethasone in STORM Part 2, and melphalan flufenamide-dexamethasone in HORIZON for the treatment of patients with triple-class exposed relapsed or refractory multiple myeloma","volume":"22","author":"Weisel K","year":"2022","unstructured":"Weisel K, Krishnan A, Schecter JM Matching-adjusted indirect treatment comparison to assess the comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 versus belantamab mafodotin in DREAMM-2, selinexor-dexamethasone in STORM Part 2, and melphalan flufenamide-dexamethasone in HORIZON for the treatment of patients with triple-class exposed relapsed or refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 22, 690\u2013701 (2022).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40261-021-01100-y","article-title":"Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician's choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS clinical trials for the treatment of patients with relapsed or refractory multiple myeloma","volume":"42","author":"Weisel K","year":"2022","unstructured":"Weisel K, Martin T, Krishnan A Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician's choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS clinical trials for the treatment of patients with relapsed or refractory multiple myeloma. Clin. Drug Investig. 42, 29\u201341 (2022).","journal-title":"Clin. Drug Investig."},{"key":"e_1_3_8_22_2","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma X","year":"2020","unstructured":"Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv doi: 2020.03.16.20037143 (2020). www.medrxiv.org\/content\/10.1101\/2020.03.16.20037143v2","journal-title":"medRxiv"},{"key":"e_1_3_8_23_2","article-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum B","year":"2020","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv doi: arXiv.2001.09765 (2020). https:\/\/arxiv.org\/abs\/2001.09765","journal-title":"arXiv"},{"key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph NS","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J. Clin. Oncol. 38, 1928\u20131937 (2020).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi UH","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33, 2266\u20132275 (2019).","journal-title":"Leukemia"},{"key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of real-world data on overall survival in multiple myeloma patients with \u22653 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD","volume":"21","author":"Usmani S","year":"2016","unstructured":"Usmani S, Ahmadi T, Ng Y Analysis of real-world data on overall survival in multiple myeloma patients with \u22653 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist 21, 1355\u20131361 (2016).","journal-title":"Oncologist"},{"key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar SK","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 31, 2443\u20132448 (2017).","journal-title":"Leukemia"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2022-0186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T10:51:13Z","timestamp":1685530273000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2022-0186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.57264\/cer-2022-0186"],"URL":"https:\/\/doi.org\/10.57264\/cer-2022-0186","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"article-number":"e220186"}}